United Kingdom — National Health Service & United States — National Institutes of Health

United Kingdom — National Health Service: The United Kingdom — National Health Service is the potential future recipient of these new diagnostic tools, aiming to make blood tests for dementia diagnosis available by 2029.

United States — National Institutes of Health: The United States — National Institutes of Health primarily funded the study on blood biomarkers, demonstrating its support for medical research.

United Kingdom — National Health Service: The United Kingdom — National Health Service in England has been criticized for its delay in updating public-facing resources to reflect the new PMOS terminology, potentially causing confusion for patients and healthcare providers.

United States — National Institutes of Health: The United States — National Institutes of Health is mentioned as a potential source for increased research funding for Polyendocrine metabolic ovarian syndrome, particularly in areas like diabetes and heart disease, due to the new name's broader scope.